Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study

Inflammatory Bowel Diseases

Volumn 7, Issue 2, 2001, Pages 83-88

  Sands, Bruce E ^a   Miehsler, Wolfgang ^b   Tremaine, William J ^b   Rutgeerts, Paul J ^c   Hanauer, Stephen B ^d   Mayer, Lloyd ^e   Targan, Stephan R ^f   Podolsky, Daniel K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF CHICAGO   (United States)

^e MOUNT SINAI HOSPITAL   (United States)

^f Cedars Sinai Hospital   (United States)

Author keywords

Infliximab; Monoclonal antibody; Steroid refractory; Tumor necrosis factor alpha; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; MERCAPTOPURINE; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CELLULITIS; CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HEMATOLOGY; HUMAN; LABORATORY TEST; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PHYSICAL EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCORING SYSTEM; TREATMENT FAILURE; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

EID: 0034777502     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200105000-00001     Document Type: Article

References (22)

1. Inflammatory bowel disease
2. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
3. Cyclosporin use in the precolectomy chronic ulcerative colitis patient: A community experience and its relationship to prospective and controlled clinical trials
4. Pro-inflammatory cytokines in inflammatory bowel disease
5. Increased production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease
6. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease
7. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease
8. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review
9. Biologic therapy for inflammatory bowel disease
10. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
11. Tumour necrosis factor and Crohn's disease
12. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha
13. Tumour-necrosis-factor antibody treatment in Crohn's disease
14. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
15. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
16. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
17. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
18. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
19. Cortisone in ulcerative colitis. Final report on a therapeutic trial
20. Endoscopic Interpretation: Normal and Pathologic Appearance of the Gastrointestinal Tract
21. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
22. Treatment of ulcerative colitis with an engineered human monoclonal anti-TNFα CDP571